Montserrado County Flag
Ebola Trial Vaccines Prove Safe For 600 Participants - Researcher
MONROVIA, March 26 (LINA) - The Ebola trial vaccines have proven safe for 600 participants in their Phase Two study in Liberia, the Co-principal Investigator of the Partnership for Research on Ebola Vaccines in Liberia (Prevail), Dr. Fatorma Bolay, has disclosed.
It can be recalled that the vaccines, ChAd3-EBO-Z, developed by GlaxoSmithKline and VSV-ZEBOV, from NewLink Genetics/Merck versus a saltwater placebo injection were introduced in the country early this year.
Addressing the Ministry of Information daily Ebola press briefing at the ministry Thursday, Bolay said a review of the interim study data conducted on the first 600 people by an independent monitoring group found no major safety concerns related to either of the two study vaccines.
Bolay stressed that participants are assigned at random to one of the three groups, adding that neither the participants nor the study staff know who received the vaccines.
“This study design is considered the gold standard for determining whether a medical intervention is safe and effective,” he pointed out.
He then commended the team’s accomplishment, adding that the information collected on the safety of the vaccines support the goal of advancing to the larger Phase Three trial.
“We thank the Liberian-US clinical research team conducting this study for their excellent work as well as the many hundreds of Liberians who stepped up to participate and contribute to this critical milestone,” Bolay indicated.